Oral Rehydration Therapy and Antidiarrheals

Introduction/Overview

Oral rehydration therapy (ORT) and antidiarrheal agents represent cornerstone interventions for the management of diarrheal illnesses across all age groups. Diarrhea remains a leading cause of morbidity and mortality worldwide, particularly among children under five years of age. The provision of balanced electrolyte solutions has dramatically reduced mortality rates in acute diarrheal disease, while antidiarrheals are employed to alleviate symptoms, improve patient comfort, and, in select circumstances, shorten disease duration. The clinical relevance of both therapeutic modalities is underscored by the high prevalence of infectious gastroenteritis, the emergence of antimicrobial resistance, and the increasing burden of functional bowel disorders.

Learning objectives for this chapter include:

• Describe the pharmacologic principles that govern the efficacy of oral rehydration solutions.
• Classify antidiarrheal medications according to mechanism of action and therapeutic indications.
• Explain the pharmacodynamic and pharmacokinetic properties of key antidiarrheal agents.
• Identify adverse effect profiles and potential drug interactions associated with oral rehydration and antidiarrheal therapies.
• Apply evidence‑based recommendations for special populations, including pregnant women, lactating mothers, pediatric patients, and individuals with renal or hepatic impairment.

Classification

Oral Rehydration Solutions (ORS)

Oral rehydration solutions are categorized primarily by their electrolyte composition, osmolarity, and intended clinical setting. The World Health Organization (WHO) standard ORS contains 75 mEq of sodium, 75 mEq of chloride, 20 mEq of potassium, 10 mEq of citrate (or 10 mEq of phosphate), and 111 g/L of glucose, yielding an osmolarity of approximately 245 mOsm/L. Variations include the expanded-oligohydration (EO) ORS, which replaces citrate with bicarbonate, and the reduced osmolarity ORS (RO-ORS) designed for use in children with severe dehydration. Commercially available products may also contain carbohydrate derivatives such as sorbitol or maltodextrin, and may be tailored for specific etiologies, such as cholera or travelers’ diarrhea.

Antidiarrheal Agents

Antidiarrheals are grouped by mechanism of action, which informs both therapeutic strategy and safety profile. The principal classes include:

• Anti‑motility agents – e.g., loperamide, which reduces intestinal transit time.
• Antisecretory agents – e.g., racecadotril, which diminishes chloride secretion.
• Anti‑inflammatory agents – e.g., bismuth subsalicylate, which mitigates mucosal inflammation.
• Antimicrobial agents with antidiarrheal properties – e.g., macrolide antibiotics, which address bacterial etiologies while reducing secretory output.

Within these categories, agents may be further differentiated by pharmacologic class: opioid receptor agonists, enkephalinase inhibitors, salicylate derivatives, and antibacterial drugs acting on bacterial toxins.

Mechanism of Action

Oral Rehydration Solutions

ORS effectiveness derives from the sodium-glucose cotransport (SGLT1) mechanism located along the proximal small intestine. Sodium and glucose are co‑absorbed via a secondary active transport process that utilizes the sodium gradient established by the Na⁺/K⁺-ATPase. The coupled movement of sodium and glucose facilitates water absorption in an osmotically coupled fashion, thereby restoring intravascular volume and correcting electrolyte disturbances. The inclusion of potassium and bicarbonate (or citrate) buffers mitigates metabolic acidosis secondary to diarrheal losses. The efficacy of ORS is maximized when the osmolarity remains below 300 mOsm/L, preventing osmotic diarrhea that may arise from overly hypertonic solutions.

Anti‑Motility Agents

Loperamide

Loperamide exerts its antidiarrheal effect by acting as a selective agonist at the μ‑opioid receptors located predominantly in the myenteric plexus of the gastrointestinal tract. Binding to these receptors activates G‑protein mediated signaling pathways that inhibit cyclic AMP (cAMP) production, leading to decreased intracellular calcium influx and reduced smooth muscle contraction. The net result is an increase in intestinal transit time, allowing for enhanced absorption of water and electrolytes. Loperamide’s limited penetration of the blood-brain barrier reduces central nervous system side effects, although high doses may exceed the blood-brain barrier threshold and produce central opioid effects.

Racecadotril

Racecadotril functions as an enkephalinase inhibitor. By preventing the degradation of endogenous enkephalins, it enhances activation of μ‑opioid receptors within the enteric nervous system. The downstream effect mirrors that of direct μ‑opioid agonists: suppression of cAMP accumulation, reduced chloride secretion, and decreased intestinal motility. This mechanism specifically targets secretory diarrhea, an advantage in bacterial toxin‑mediated diarrheal diseases.

Anti‑Inflammatory Agents

Bismuth Subsalicylate

Bismuth subsalicylate possesses both anti‑inflammatory and antimicrobial properties. Its anti‑inflammatory action is attributed to inhibition of prostaglandin synthesis via salicylate release, while its antimicrobial effect involves direct interaction with bacterial cell walls and inhibition of enterotoxin production. Additionally, bismuth forms a protective coating over the mucosa, thereby reducing mucosal injury and facilitating restitution. The combined effect yields both symptomatic relief and reduction in pathogen burden in certain infectious diarrheas.

Antimicrobial Agents with Antidiarrheal Properties

Macrolide antibiotics, such as azithromycin, demonstrate antidiarrheal activity by suppressing pathogens responsible for bacterial gastroenteritis. Their mechanisms include inhibition of bacterial protein synthesis via binding to the 50S ribosomal subunit, thereby curtailing toxin production and reducing intestinal inflammation. While primarily bacteriostatic, their therapeutic benefit in diarrheal disease is derived from the reduction of secretory stimuli.

Pharmacokinetics

Oral Rehydration Solutions

ORS components are primarily absorbed or retained within the gastrointestinal lumen; thus, traditional pharmacokinetic parameters such as bioavailability, distribution volume, metabolism, and excretion are not applicable in the conventional sense. The absorption of sodium, chloride, potassium, and glucose occurs in the proximal small intestine via active transport mechanisms, while the remaining electrolytes are absorbed along the colon through passive diffusion. The rate of dissolution and electrolyte absorption is influenced by gastrointestinal motility, which is itself moderated by the presence of antidiarrheals when concomitant therapy is used.

Loperamide

Loperamide is absorbed extensively in the small intestine, with a bioavailability of approximately 20 % due to extensive first‑pass metabolism by CYP3A4. It exhibits a large volume of distribution (estimated 2.8 L/kg) and is highly protein‑bound (≈98 %). Metabolism occurs primarily via CYP3A4 to inactive metabolites, followed by hepatic clearance. The terminal half‑life of loperamide is approximately 4–6 hours, permitting twice‑daily dosing for chronic conditions. Peak plasma concentrations are reached within 1–2 hours post‑dose. The drug’s lipophilicity facilitates its accumulation in the enteric tissues, sustaining local μ‑opioid receptor activation.

Bismuth Subsalicylate

Following oral administration, bismuth subsalicylate dissociates into bismuth ions and salicylate. The salicylate component is absorbed systemically via passive diffusion; its bioavailability is approximately 70 %. The bismuth ions remain largely within the gastrointestinal tract, forming insoluble complexes that exert local effects. Systemic absorption of bismuth is minimal, although high doses may result in detectable serum concentrations. Bismuth is eliminated via feces as inorganic salts; renal excretion is negligible for the bismuth component, whereas salicylate is metabolized in the liver and excreted renally. The half‑life of salicylate is about 3–4 hours; bismuth’s residence time in the gut may extend beyond the systemic half‑life.

Racecadotril

Racecadotril is rapidly absorbed in the small intestine, with a bioavailability of ~70 %. The drug undergoes first‑pass hydrolysis by esterases to produce the active metabolite, thiorphan. Thiorphan is distributed widely, exhibiting a volume of distribution of ~1.5 L/kg. It is largely excreted unchanged in the urine; the terminal half‑life of thiorphan is approximately 1.5 hours. Due to its rapid metabolism, the therapeutic effect is mediated by the active metabolite rather than the parent compound.

Therapeutic Uses/Clinical Applications

Oral Rehydration Therapy

ORS is indicated for the prevention and treatment of dehydration associated with acute watery diarrhea, including cholera, travelers’ diarrhea, viral gastroenteritis, and bacterial enteritis. It is also employed in the management of postoperative ileus, chemotherapy‑induced diarrhea, and in patients with malabsorption syndromes. The WHO standard ORS is the recommended first‑line therapy in resource‑limited settings, while reduced osmolarity ORS is preferred for children presenting with severe dehydration to mitigate the risk of hyperosmolarity‑induced adverse effects.

Antidiarrheal Agents

Loperamide is used for the symptomatic treatment of acute, non‑severe diarrhea and irritable bowel syndrome (IBS) with diarrhea. Off‑label applications include the management of opioid‑induced constipation and postoperative ileus, although caution is advised due to potential for paralytic ileus.

Racecadotril is indicated for acute secretory diarrhea, especially in children with bacterial toxin‑mediated enteritis. Its use is limited in cases of dysentery or colitis where motility reduction may impede pathogen clearance.

Bismuth Subsalicylate is employed for travelers’ diarrhea, Helicobacter pylori eradication regimens, and as adjunct therapy in gastroenteritis caused by enterotoxigenic Escherichia coli. It is also indicated for the treatment of gastric ulceration and as a component of multimodal antiemetic protocols.

Macrolide Antibiotics (e.g., azithromycin) are reserved for bacterial infections such as Campylobacter, Shigella, and certain strains of Salmonella. Their antidiarrheal efficacy is secondary to bacterial suppression and toxin inhibition.

Adverse Effects

Oral Rehydration Solutions

ORS is generally well tolerated. Potential adverse effects include mild abdominal discomfort, bloating, or transient diarrhea if the solution is administered in volumes exceeding tolerable limits. In rare instances, hypernatremia may arise from excessive sodium intake, particularly in patients with impaired renal excretion.

Loperamide

Common side effects encompass constipation, abdominal cramps, nausea, and flatulence. Rare but serious events involve severe constipation leading to paralytic ileus, especially in patients with underlying ileus or intestinal obstruction. Central nervous system effects (e.g., sedation, dizziness) may occur at supratherapeutic doses or when combined with other CNS depressants.

Racecadotril

Adverse events are infrequent and include nausea, abdominal discomfort, and, in rare cases, hypersensitivity reactions. No significant hepatotoxicity or nephrotoxicity has been reported at therapeutic doses.

Bismuth Subsalicylate

Adverse effects encompass black discoloration of the tongue and stool, nausea, vomiting, abdominal pain, and, in susceptible individuals, aspirin‑related gastrointestinal irritation. Chronic exposure may lead to bismuth accumulation, manifesting as neurotoxicity (e.g., encephalopathy) and renal dysfunction, though such outcomes are uncommon at standard therapeutic doses.

Macrolide Antibiotics

Common side effects include diarrhea, abdominal pain, nausea, and dysgeusia. Prolonged use may precipitate Clostridioides difficile colitis. QT interval prolongation is a recognized cardiac risk, particularly when combined with other QT‑prolonging agents.

Drug Interactions

Loperamide

Loperamide interacts with drugs that inhibit CYP3A4 (e.g., ketoconazole, clarithromycin), leading to increased systemic absorption and potential central opioid toxicity. Co‑administration with other anticholinergic or CNS depressant agents may exacerbate sedation. Loperamide may also potentiate the constipation‑inducing effects of opioids.

Racecadotril

As an enkephalinase inhibitor, racecadotril may augment the anticholinergic effects of other drugs acting on the enteric nervous system. No major interactions with antibiotics or NSAIDs have been documented; however, caution is advised when combined with other secretagogues that may counteract its antisecretory effect.

Bismuth Subsalicylate

Bismuth can interfere with the absorption of tetracyclines and fluoroquinolones, reducing their bioavailability. Concurrent use with other salicylate‑containing medications may increase the risk of salicylate toxicity. Bismuth may also precipitate with calcium or magnesium supplements, potentially reducing the therapeutic effect of those agents.

Macrolide Antibiotics

Macrolides can inhibit CYP3A4, thereby elevating plasma concentrations of concomitant medications metabolized by this pathway (e.g., statins, benzodiazepines). They may also compete for the same transporter proteins (P‑gp), affecting drug disposition. Careful monitoring for QT prolongation is recommended when macrolides are co‑administered with other QT‑prolonging agents.

Special Considerations

Pregnancy and Lactation

ORS is considered safe throughout pregnancy and lactation, as its constituents are physiologic electrolytes and glucose. Loperamide is classified as category B; limited data suggest minimal placental transfer, yet high doses may pose central nervous system risks. Racecadotril has limited human data; however, animal studies indicate no teratogenicity, prompting cautious use. Bismuth subsalicylate is generally avoided in pregnancy due to salicylate content, though short courses may be acceptable in specific circumstances. Macrolide antibiotics are category B or C, with azithromycin frequently used in pregnancy for certain infections.

Pediatric and Geriatric Populations

Pediatric dosing of ORS is weight‑based, with recommendations of 100–200 mL/kg over 4–6 hours for mild dehydration and higher volumes for severe cases. Loperamide dosing in children under 12 years is typically 0.15 mg/kg per dose, with a maximum of 4 mg per day; caution is advised due to the risk of constipation and potential for paradoxical exacerbation of diarrhea. Racecadotril dosing is 10 mg/kg per dose, up to 30 mg/kg/day. Bismuth subsalicylate is generally contraindicated in children under 6 months due to the risk of Reye syndrome. In geriatric patients, altered pharmacokinetics necessitate dose adjustments, particularly for drugs metabolized by the liver or excreted by the kidneys. Monitoring of renal function is advisable when prescribing drugs with renal clearance.

Renal and Hepatic Impairment

ORS remains appropriate regardless of renal status; however, hypernatremia risk increases in renal insufficiency, necessitating close monitoring of serum electrolytes. Loperamide clearance is hepatic; patients with hepatic impairment may experience prolonged drug exposure, increasing the risk of central opioid effects. Racecadotril is eliminated primarily by the kidneys; dose reduction may be required in patients with reduced glomerular filtration rate. Bismuth accumulation can occur in renal failure, heightening the risk of neurotoxicity. Macrolides undergo hepatic metabolism; caution is warranted in patients with hepatic dysfunction, and dose adjustments may be necessary.

Summary / Key Points

• ORS restores intravascular volume and corrects electrolyte imbalance via the sodium‑glucose cotransport system; osmolarity should remain below 300 mOsm/L to prevent osmotic diarrhea.
• Loperamide reduces intestinal motility by activating μ‑opioid receptors; its efficacy is limited by potential for severe constipation and central opioid toxicity at high doses.
• Racecadotril acts as an enkephalinase inhibitor, reducing chloride secretion and shortening secretory diarrhea.
• Bismuth subsalicylate offers anti‑inflammatory and antimicrobial benefits but may cause black stool, nausea, and, with chronic use, neurotoxicity.
• Macrolide antibiotics suppress bacterial pathogens and toxin production, providing secondary antidiarrheal effects.
• Drug interactions with CYP3A4 inhibitors, anticholinergics, and other secretagogues can modify the safety profile of antidiarrheals.
• Special populations require careful dosing adjustments: weight‑based ORS in children, dose limits in pregnancy, and renal/hepatic monitoring in older adults.
• Monitoring of serum electrolytes, renal function, and potential adverse reactions is essential for safe therapy.

These principles serve as a foundation for evidence‑based management of diarrheal diseases, ensuring optimal patient outcomes while minimizing adverse events.

References

1. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
2. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
3. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
4. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.